Cerebral (Fatal) Malaria - Pipeline Review, H2 2016 - Treatment By Antimalarial, Antiseizure & Anti Inflammatory Medications - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Cerebral (Fatal) Malaria - Pipeline Review, H2 2016" report to their offering.

Cerebral malaria is the most dangerous and life-threatening form of malaria that affects the brain. It is caused by plasmodium falciparum, a protozoan parasite. Plasmodium gets transmitted to human via infected mosquito bites. Symptoms include fever, head ache, muscle pain, low blood pressure, coma and convulsions. Treatment includes antimalarial, antiseizure and anti inflammatory medications.

This report provides comprehensive information on the therapeutic development for Cerebral malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral malaria and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • Callaghan Innovation Research Ltd
  • Eisai Co Ltd
  • Lipocure Ltd

Key Topics Covered:

  1. Introduction
  2. Cerebral malaria Overview
  3. Therapeutics Development
  4. Pipeline Products for Cerebral malaria - Overview
  5. Pipeline Products for Cerebral malaria - Comparative Analysis
  6. Cerebral malaria - Therapeutics under Development by Companies
  7. Cerebral malaria - Therapeutics under Investigation by Universities/Institutes
  8. Cerebral malaria - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Cerebral malaria - Products under Development by Companies
  13. Cerebral malaria - Products under Investigation by Universities/Institutes
  14. Cerebral malaria - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/dbtnjl/cerebral_fatal

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs